Navigation Links
Elekta Sees Record Attendance and Record Number of Submitted Abstracts at International Leksell Gamma Knife(R) Society Meeting in Quebec, Canada
Date:5/21/2008

STOCKHOLM, Sweden, May 21 /PRNewswire/ -- At the 14th International Leksell Gamma Knife(R) Society Meeting on May 18-22, over 500 participants including neurosurgeons, radiation oncologists and other medical specialists using Leksell Gamma Knife for treatment of tumors and other brain disorders convened at the historic Chateau Frontenac Hotel in Quebec, Canada. During the meeting, 260 oral and poster presentations covered treatment of malignant and benign brain tumors, functional neurosurgery, imaging and biology as well as physics and technology. Wednesday, May 21, the prestigious Pioneers in Radiosurgery Award was presented to John Flickinger, M.D., Professor of Radiation Oncology and Neurological Surgery at the University of Pittsburgh for his early pioneering work on prediction of complications following Gamma Knife(R) surgery.

(Logo: http://www.newscom.com/cgi-bin/prnh/20020318/ELEKTALOGO )

The Leksell Gamma Knife Society was established in 1989 to provide a forum for Gamma Knife users to share information, experiences, clinical techniques and advanced scientific research in their quest to non-invasively treat an expanding number of brain disorders. The meetings, which are held biannually, result in a large number of clinical publications, in recent years published as a supplement to Journal of Neurosurgery. The Society plays an important role in increasing the visibility and acceptance of Gamma Knife surgery in the worldwide medical community, among healthcare providers and among patients. The open sharing of results and experiences allows all Gamma Knife users to maintain leadership in the field of intracranial radiosurgery, based on the most recent clinical advancements.

The 14th meeting in Quebec is held with the theme, "Je me Souviens ... " ("I Remember ... "), which is the motto of Quebec. The theme connects the celebration of Quebec 400 year lo
'/>"/>

SOURCE Elekta, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Johns Hopkins to add Elekta Synergy S(R) to Cancer Treatment Lineup
2. Elekta Demonstrates Commitment to Stereotactic Innovation at EANS
3. Elekta To Showcase Innovations in Radiotherapy and Unveil New Product That Expands Cancer Treatment Availability
4. Elekta Contract Provides Sisters of Mercy Health System Access to Leading Radiation Therapy Solutions
5. Elekta Launches New Linear Accelerator at 2007 ESTRO to Expand Cancer Treatment Availability
6. Elekta Brings Intelligent Ways to Manage Motion During Cancer Treatment to ESTRO
7. Elekta Displays Complete Volumetric Intensity Modulated Arc Therapy Solutions at ESTRO
8. Elekta Announces New Cancer Care Solutions and Highlights Personalized Efficiency at ASTRO 2007
9. Elekta Announces Elekta Infinity - a New System for Faster and More Precise Treatment of Cancer Tumors
10. Beaumont Hospital, Royal Oak Treats Its First Patients With Elekta Axesse
11. Elekta Showcases Stereotactic Systems for Cancer Care at Astro 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/2/2008)...y Technology Receive Funding, From Allied Minds to... of Aliquots, BOST...d investment,corporation specializing in early sta...y,s Office of Technology Development, and Northeas...t Instruments, LLC, a new,spin-out focused on the ...
(Date:7/2/2008)...-- Pearl Therapeutics, Inc.,a biopharmaceutical c...iseases, today announced that it has completed the...s financing was executed as an extension to,its fi...articipating in the,internal round were Pearl,s ex...s, 5AM Ventures and Nektar Therapeutics. In total,...
(Date:7/2/2008)...-- Research conducted at The,Walter and Eliza Hall... a,major licensing agreement signed between Austra...nd Germany-based pharmaceutical company, Merck,Ser...nt, Merck Serono will seek,to develop new treatmen...e,conditions. These prospective treatments will be...
(Date:7/2/2008).../ -- WuXi PharmaTech (NYSE:,WX), a leading pharmac...,and development outsourcing company with operatio... that it has appointed Mr. Bob Zhu as Vice Preside...m.com/cgi-bin/prnh/20040705/CNM002LOGO ), Prior ... of Asia Human,Resources with Electronic Arts (EA)...
Breaking Biology Technology:Investment Firm Allied Minds to Commercialize New Frozen Aliquotter Technology with Two Local Major Universities. 2Pearl Therapeutics Closes $18 Million Financing Round Led By Committed Investors 2MS Drug Development Agreement Based on WEHI's Medicinal Chemistry 2WuXi PharmaTech (NYSE: WX) Appoints Mr. Bob Zhu as VP of HR 2
...echnology , a unit of Fisher Biosciences, has cont... to distribute GenTel,s trademarked PATH brand thi...use of GenTel technology in developing new protein...ry. GenTel slides are specifically designed for pr...of disease biomarkers to improve the safety and ef...
...th the recently developed APR reactor UW-Madison ...s. In 2002, UW stem cell pioneer James Thomson w...ge and Sergey Brin. This year, it might be James D... two men will be honored as New Fellows of the New...s itself a "global meeting ground, a virtual think...
...nst CoreComm Voyager, Inc . for violating Wiscons... by the state attorney general. , ,CoreComm, a Del...s and related services to Wisconsin customers, man...nsin-based internet provider subsequently acquired...y Circuit Court, alleged that CoreComm failed to c...
...ebsite for the new century, complete with RSS news...s of everything important to the average person, s...ses and changes in the status of known sex offende...ted shades of gray, blue and tan. It contains link...et a free credit report, and gives up-to-the minut...
Other Biology Technology:Wisconsin scientists to be recognized for innovative biofuel technology 2Wisconsin scientists to be recognized for innovative biofuel technology 3CoreComm slapped by AG for violating telecommunications laws 2State web site needs overhaul 2State web site needs overhaul 3State web site needs overhaul 4
(Date:7/3/2008)...hers at the David Geffen School of Medicine at UCL... known as sodium glucose co-transporters (SGLTs), ...teins are used in the treatment of chronic diarrhe...f millions of children each year. The solution of ...new drugs designed to treat patients with diabetes...
(Date:7/3/2008)...bservation satellites have provided vital informat...icularly long crisis response window following the...n 2 and 3 May 2008. , Immediately after the disa...tarian Affairs (OCHA) asked the International Char... ,the Charter, for support by providing immediate...
(Date:7/3/2008)...IS Want to slow the signs of aging and live longe...tting back on calories could be a promising strate...o slow the aging process in rats and mice. While s...cts the aging process in rodents, one popular hypo...oid hormone, triiodothyronine (T3), which then slo...
(Date:7/2/2008)...GSTON, R.I. July 2, 2008 Standing in a greenhous... was smiling even though it appeared that somethin...pecies of grass she planted last February in hundr...ofessor of turf science wasn,t surprised. That,s ...saltier water for five months, and few varieties o...
Breaking Biology News(10 mins):UCLA researchers clarify function of glucose transport molecule 2Extended cyclone relief efforts aided from space 2Extended cyclone relief efforts aided from space 3Looking for the Founatain of Youth? Cut your calories, research suggests 2Search for salt tolerant grasses aims to improve roadside plantings 2Cryo Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics Inc 2813 1Cryo Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics Inc 2813 2Cryo Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics Inc 2813 3Cryo Cell Announces Research Collaboration Agreement with Saneron CCEL Therapeutics Inc 2813 4Access Pharmaceuticals Announces 242 7 Million New Equity 2811 1Access Pharmaceuticals Announces 242 7 Million New Equity 2811 2Access Pharmaceuticals Announces 242 7 Million New Equity 2811 3Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer 1282 1Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer 1282 2Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer 1282 3Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer 1282 4Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads 2809 1Merial to Screen Chimerix Chemical Library for Animal Health Drug Leads 2809 2
...diers guarding a castle gate, multiple genetic def...wdery mildew disease, according to a new study. Po...s that attacks more than 9,000 species, including ...ural plants such as roses and cucumbers. The resea...in of the Carnegie Institution,s Department of Pla...
...reatment for stroke has taken a major step forward...al trial. , Researchers at The University of Manch...rally occurring protein called IL-1ra protects bra...y Professor Nancy Rothwell and Dr Pippa Tyrrell, h...ial of IL-1ra in patients, which are published in ...
...t accompanied the recent drought was the underlyin...ughout the Southwest, according to new research. ,...osystem for decades. Hotter temperatures coupled w...bal climate change models. The new finding suggest...global climate change. , "We documented a massive...
...e experiment has resulted in one of the longest re...ened a new door for anti-aging research in humans.... extra copy of the SIR2 gene can promote longevity...was covered widely and incorporated into anti-agin...gy companies. , Now, molecular geneticists at the...
Other Biology News:Genetic defenders protect crops from fungal disease 2Genetic defenders protect crops from fungal disease 3Stroke treatment a step closer after trial 2Underlying cause of massive pinyon pine die-off revealed 2Underlying cause of massive pinyon pine die-off revealed 3Underlying cause of massive pinyon pine die-off revealed 4New technique multiplies life span in simple organisms 2New technique multiplies life span in simple organisms 3
Rabbit polyclonal to TAB1 ( Abpromise for all tested applications). entrezGeneID: 10454 SwissProtID: Q15750
Rabbit polyclonal to NIRF ( Abpromise for all tested applications). Antigen: Synthetic peptide derived from residues 186-235 of human NIRF. Entrez Gene ID: 115426 Swiss Protein ID: Q96PU
Rabbit polyclonal to DcR2 ( Abpromise for all tested applications). entrezGeneID: 8793 SwissProtID: Q9UBN6
Fau I from New England Biolabs
Biology Products: